Submission Details
| 510(k) Number | K251779 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 10, 2025 |
| Decision Date | December 03, 2025 |
| Days to Decision | 176 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
K251779 is an FDA 510(k) clearance for the Omnipod 5 algorithm, a Interoperable Automated Glycemic Controller (Class II — Special Controls, product code QJI), submitted by Insulet Corporation (Acton, US). The FDA issued a Cleared decision on December 3, 2025, 176 days after receiving the submission on June 10, 2025. This device falls under the Chemistry review panel. Regulated under 21 CFR 862.1356.
| 510(k) Number | K251779 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 10, 2025 |
| Decision Date | December 03, 2025 |
| Days to Decision | 176 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
| Product Code | QJI — Interoperable Automated Glycemic Controller |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.1356 |
| Definition | An Interoperable Automated Glycemic Controller Is A Device Intended To Automatically Calculate Drug Doses Based On Inputs Such As Glucose And Other Relevant Physiological Parameters, And To Command The Delivery Of Such Drug Doses From A Connected Infusion Pump. Interoperable Automated Glycemic Controllers Are Designed To Reliably And Securely Communicate With Digitally Connected Devices To Allow Drug Delivery Commands To Be Sent, Received, Executed, And Confirmed. Interoperable Automated Glycemic Controllers Are Intended To Be Used In Conjunction With Digitally Connected Devices For The Purpose Of Maintaining Glycemic Control. |